Please use this identifier to cite or link to this item:
|Title:||Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis.||Austin Authors:||Sathianathen, Niranjan J;Pan, Henry Y C;Lawrentschuk, Nathan;Siva, Shankar;Azad, Arun A;Tran, Ben;Bolton, Damien M ;Murphy, Declan G||Affiliation:||Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Surgery (University of Melbourne)
|Issue Date:||18-Nov-2022||metadata.dc.date:||2022||Publication information:||Urologic Oncology 2022||Abstract:||There have been a growing number of treatment options available for men with metastatic castration-sensitive prostate cancer. Not only have newer agents entered the clinical landscape, there is a trend toward treatment intensification by combining multiple agents simultaneously. We aim to assess the best contemporary treatment option for men with mCSPC.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/31746||DOI:||10.1016/j.urolonc.2022.10.016||ORCID:||Journal:||Urologic Oncology||PubMed URL:||36411180||ISSN:||1873-2496||Type:||Journal Article||Subjects:||Chemotherapy
|Appears in Collections:||Journal articles|
Show full item record
checked on May 29, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.